Drugs developer Nuformix PLC (LON:NFX) said in its half-year report it has made significant progress. The group, which uses cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, has focused all its efforts and resources into advancing its lead programmes and during the period it successfully completed its first clinical development study for its lead product NXP001. The study validated the group’s platform and demonstrated it can rapidly translate its applications of cocrystal technology into human use.
Polarean Imaging PLC (LON:POLX), the medical-imaging technology company, has delivered and installed its latest research unit order for a 9820 Xenon Polariser system. The order was placed by the University of Iowa Hospitals and Clinics. The total number of Polarean’s polarisers that are either installed or on order remains 25.
Online gaming platform operator Nektan PLC (LON:NEK) says its shares will be suspended on 2 January ahead of the possible sale of its B2C platform. Talks over the disposal and subsequent restructuring of the company are at an advanced stage and due to that Nektan says it is unlikely it will publish its accounts by the end of the year as required, which will mean automatic suspension for its shares. The accounts are expected to be published later in January.
CentralNic Group PLC (LON:CNIC), the company that supplies domain name and web services subscriptions over its proprietary platforms to millions of businesses globally, has completed its acquisition of Team Internet, a web service provider based in Munich, Germany. In a Christmas Eve statement, Ben Crawford, CEO of CentralNic, said: “The acquisition of Team Internet is a natural extension of CentralNic’s domain sales business and a major step in adding domain related web services to CentralNic’s service offering. It is another web-based recurring revenue business that will be significantly earnings enhancing for the financial year ending 31 December 2020.”
Estimates of higher future nickel prices underline the significant value in its projects at Araguaia and Vermelho in Brazil said Horizonte Minerals PLC (LON:HZM) in a letter to shareholders. Nickel has been the best performing metal on the London Metal Exchange this year rising by 27% to US$13,960/t on average, a figure in line with the assumptions in Araguaia’s feasibility study.
A write-off of its stake in ferrosilicon producer Steelmin and Botswana diamond explorer Amulet sent Red Rock Resources PLC (LON:RRR) into the red in the year to June. Red Rock also decided not to write back any of the £5.28mln impairment of its Kenya gold assets as new licences have yet to be issued in spite of a settlement with the country’s ministry. The company fared better with its investment in manganese producer Jupiter Mines, where dividends received rose to £750,000 from £250,000.
Summit Therapeutics (LON:SUMM) (NASDAQ:SMMT), a leader in antibiotic innovation, announced that its subscription and placing of new ordinary shares and warrants to raise approximately US$50mln – which was approved by shareholders at the company’s general meeting held on 23 December 2019 – has completed. It also noted that completion of the fundraising means that the proposed restructuring of the company’s board of directors is now effective, with Glyn Edwards taking over a chairman in addition to his role as the company’s chief executive officer.
Regency Mines PLC (LON:RGM) announced that as part of its recent placing, approved by shareholders on Monday, its new executive chairman James Parsons has purchased 727,273 new ordinary shares giving him a 0.8% holding in the company.
Salt Lake Potash Limited (LON:SO4) (ASX:SO4) announced that a General Meeting of the company will be held at the Conference Room, Ground Floor, BGC Centre, 28 The Esplanade, Perth, Western Australia on Wednesday 29 January 2020 at 1:00pm (WST). The group said the meeting will consider the second tranche of the placement announced on 6 December 2019, as well as ratifying the first tranche of placement shares in order to refresh the company’s placement capacity.